Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (September 2021)
24 slides from Enveric Biosciences's investor presentation, Sep 17, 2021
Slide 1: Investor Deck September 2021
Investor Deck September 2021 NASDAQ: ENVB
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu
Slide 3: EnvericBio – Creating the Next Generation of Psychedelics
EnvericBio – Creating the Next Generation of Psychedelics A discovery platform to create novel next-generation psychedelics to address the global mental health crisis. • Significant first-mover advantage in IP to cover “greenfield” opportunities • Achieve greater market penetration by un- constraini
Slide 4: Executing with Experience and Passion: Pharma & Biotech Leadership
Executing with Experience and Passion: Pharma & Biotech Leadership Management Team Board of Directors Dr. Joseph Tucker Mr. Avani Kanubaddi David Johnson Dr. Joseph Tucker Chief Executive Officer & Chief Operating Officer Executive Chairman Chief Executive Officer & Director Director Former CEO of W
Slide 5: World Class Advisors – Research and Clinical
World Class Advisors – Research and Clinical Michael J. Zelefsky, M.D. Arash Asher, M.D. Chairman Scientific Advisor Dr. Michael Zelefsky is a board-certified radiation oncologist and co-leader of Memorial Dr. Arash Asher is the Director of Cancer Rehabilitation and Survivorship at the Sloan Ketteri
Slide 6: Enveric Bio: Rapidly Advancing Next Gen Mental Health for the Mind and Body
Enveric Bio: Rapidly Advancing Next Gen Mental Health for the Mind and Body A Compelling Investment Thesis • Strong Financial Platform - NASDAQ Traded • Disruptive IP Portfolio - Psybrary and PsyAI • Un-constraining current psychedelic market paradigm/model • Experienced Team from Discovery through
Slide 7: Execute on Clinical Assets and Invest in Discovery Assets
Execute on Clinical Assets and Invest in Discovery Assets Strong Short-, Medium- and Long-Term Pipeline Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Major Next Steps Timing EVM201 CRD Molecule Selection Q1 2022 EVM202 PTSD Molecule Selection Q3 2023 EVM203 Anxiety Molecule Selection Q4 2
Slide 8: Next Generation Treatments
Next Generation Treatments We believe the aggregate addressable market for the compounds in the Psybrary could exceed $100B+ 3rd Generation Psychedelics MIND Hallucinogenic · Non-Hallucinogenic $98+ ADHD $25B+1 BILLION Depression $12B+2 BODY PTSD $990M+3 Anxiety $7B+4 Market $147+ Substance Abuse An
Slide 9: Market and Investor Validation
Market and Investor Validation Traditional Pharma Regulatory Pathway draws in Institutional Investors Market Validation • J&J Spravato first • FDA Breakthrough • Bio-pharma and Life Science approved Psychedelic Status for 2 Drugs Institutional Investors are putting money to work in a • FDA Breakthro
Slide 10: EnvericBio – Next Generation Approach
EnvericBio – Next Generation Approach Solving for the limitations Market Limitations Enveric Solution • Classic Molecules Patentability? • 15 Patent Families • Clinical Service Model – Scalable? • Including Non-hallucinogenic Psychedelics • Limited molecules equals limited options? • Psybrary & PsyA
Slide 11: Psychedelics – Addressing the Mind
Psychedelics – Addressing the Mind Inventing Next Generation Molecules for Mental Health
Slide 12: Generations – A Rapidly Evolving Science Base
Generations – A Rapidly Evolving Science Base Next Generation of Molecules (AI-Driven, Proprietary, & Targeted) Chemically Modified into Prodrugs — A step wise enhancement Classic Psychedelics with Limited Patent Potential SSRIs/Current options 12
Slide 13: Patient Flow – Opportunity to Expand Market Exponentially
Patient Flow – Opportunity to Expand Market Exponentially Current Therapist-delivery model limits the Patient Population Served Gen 1 & 2 Psychedelic Model Psychotherapy with Psychedelics Gen 3 - NCE Model 13
Slide 14: Industry Landscape: 80% of Molecules are Gen1
Industry Landscape: 80% of Molecules are Gen1 Company Type Indication Drug Gen 1/2/3 Phase 1 Phase 2 Phase 3 Market Cap DemeRx NASDAQ: ATAI Opioid Use Disorder DMX-NB1 Noribogaine Gen 1 x x $2.4B Psiliocybin Compass NASDAQ: CMPS Treatment Resistant Depression Gen 1 x x $1.4B COMP360 MindMed NASDAQ:
Slide 15: Discovery Team + World-class Laboratories
Discovery Team + World-class Laboratories 15
Slide 16: SynBio and SynChem: Experience, Expertise and Breadth
SynBio and SynChem: Experience, Expertise and Breadth 16
Slide 17: Massive Diversity Enables Generation 2 & 3 Drug Optimization
Massive Diversity Enables Generation 2 & 3 Drug Optimization Broad Intellectual Property Coverage Derivative Molecules Classic Molecule Target Patent Filings Protected Psilocybin & 15 Filed 125 Million DMT Patents Mescaline/ 0/8 Patents (1) 100 Million (1) MDMA (1) These figures represent the Compan
Slide 18: PsyAI – Organizing and Analyzing the vast Psybrary
PsyAITM – Organizing and Analyzing the vast Psybrary 18
Slide 19: Cannabinoids – Addressing the Body
Cannabinoids – Addressing the Body Promising short and mid-term clinical assets
Slide 20: Human Endocannabinoid System Discovered in the 90s
Human Endocannabinoid System Discovered in the 90s Cannabinoids Tap Into Natural Mechanisms Of Human Body “In the 1990’s, scientists discovered endocannabinoids, the natural cannabis-like molecules produced by the human body. Scientists CB1 CB2 CB1 Receptors Target CB2 Receptors Target began to real
Slide 21: Cannabis & Inflammation
Cannabis & Inflammation Several leading academic institutions from around the globe have been researching the potential for cannabis to treat inflammation, with compelling results. 21
Slide 22: Radiation Dermatitis (RD): $1B Opportunity to Improve High Unmet Need
Radiation Dermatitis(RD): $1B Opportunity to Improve High Unmet Need Current Problem Scientific Hypothesis Enveric Solution Path • 50% cancer patients → radiation • Scientific Evidence: cannabinoids • Enveric novel formulation for RD impacting inflammation • IND Filing Q2 2022 • Radiation Dermatitis
Slide 23: First Nationally Listed Psychedelic and Cannabinoid Biotech Company
:ENVB First Nationally Listed Psychedelic and Cannabinoid Biotech Company Cash and Cash equivalents as of June 30th, 2021 • Cash On-hand - $20.6MM • Debt - Zero Capital Raise • Jan 2021: $9.5 million • Feb 2021: $12.1 million • Warrant exercise (Mar 2021): $3.3 million Issued Shares • Outstanding sh
Slide 24: Building a Discovery & Clinical Platform to Serve the Mind and Body
BUILDING A DISCOVERY & CLINICAL PLATFORM TO SERVE THE MIND AND BODY INVESTOR PRESENTATION (NASDAQ: ENVB) For more information please contact: [email protected]
Enveric Biosciences — Investor Presentation (September 2021) on 6ix